Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Levonorgestrel Butanoate
1. 86679-33-6
2. Levonorgestrel Butanoate
3. L929cbb126
4. 13-ethyl-17alpha-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one Butyrate
5. Einecs 289-270-0
6. Unii-l929cbb126
7. Schembl5078825
8. Dtxsid801166916
9. [(8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-oxo-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-yl] Butanoate
10. Q27282852
11. (17alpha)-13-ethyl-17-(1-oxobutoxy)-18,19-dinorpregn-4-en-20-yn-3-one
12. 13-ethyl-17.alpha.-hydroxy-18,19-dinorpregn-4-en-20-yn-3-one Butyrate
13. 18,19-dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-(1-oxobutoxy)-, (17.alpha.)-
14. (8r,9s,10r,13s,14s,17r)-13-ethyl-17-ethynyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1h-cyclopenta(a)phenanthren-17-yl Butyrate
| Molecular Weight | 382.5 g/mol |
|---|---|
| Molecular Formula | C25H34O3 |
| XLogP3 | 4.7 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 382.25079494 g/mol |
| Monoisotopic Mass | 382.25079494 g/mol |
| Topological Polar Surface Area | 43.4 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 740 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 6 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Contraceptives, Oral, Hormonal
Oral contraceptives which owe their effectiveness to hormonal preparations. (See all compounds classified as Contraceptives, Oral, Hormonal.)
ABOUT THIS PAGE
A Levonorgestrel Butyrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Levonorgestrel Butyrate, including repackagers and relabelers. The FDA regulates Levonorgestrel Butyrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Levonorgestrel Butyrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Levonorgestrel Butyrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Levonorgestrel Butyrate supplier is an individual or a company that provides Levonorgestrel Butyrate active pharmaceutical ingredient (API) or Levonorgestrel Butyrate finished formulations upon request. The Levonorgestrel Butyrate suppliers may include Levonorgestrel Butyrate API manufacturers, exporters, distributors and traders.
click here to find a list of Levonorgestrel Butyrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Levonorgestrel Butyrate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Levonorgestrel Butyrate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Levonorgestrel Butyrate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Levonorgestrel Butyrate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Levonorgestrel Butyrate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Levonorgestrel Butyrate suppliers with NDC on PharmaCompass.
Levonorgestrel Butyrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Levonorgestrel Butyrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Levonorgestrel Butyrate GMP manufacturer or Levonorgestrel Butyrate GMP API supplier for your needs.
A Levonorgestrel Butyrate CoA (Certificate of Analysis) is a formal document that attests to Levonorgestrel Butyrate's compliance with Levonorgestrel Butyrate specifications and serves as a tool for batch-level quality control.
Levonorgestrel Butyrate CoA mostly includes findings from lab analyses of a specific batch. For each Levonorgestrel Butyrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Levonorgestrel Butyrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Levonorgestrel Butyrate EP), Levonorgestrel Butyrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Levonorgestrel Butyrate USP).
LOOKING FOR A SUPPLIER?
